Coveney Kevin Michael 4

What Happened
Kevin Michael Coveney, Chief Financial Officer of Enveric Biosciences, was granted 133,333 restricted stock units (RSUs) on 2026-06-01 (transaction coded as an award, A). The grant shows $0.00 cash paid for the RSUs; each RSU entitles the holder to one share of common stock upon vesting. This is a grant (not a market purchase or sale), so it represents future potential equity rather than an immediate investment or cash transaction.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (timely filing).
• Grant: 133,333 RSUs; per filing consideration = $0.00.
• Vesting (per footnote): one-fourth vests on the one-year anniversary, then an additional one‑thirty‑sixth of the RSUs vests each month following the first vesting date; any remaining RSUs vest on the fourth anniversary. Vesting is conditioned on continued employment.
• Each vested RSU converts to one share of common stock upon vesting.
• Shares owned after the grant: not specified in the provided filing details.
• Transaction type: Award/Grant (not a purchase or sale); no 10b5-1 plan or tax-withholding details disclosed in the footnote.

Context
RSU grants are common executive compensation that vest over time and are generally intended to retain and incentivize executives; they do not represent an immediate market purchase or sale. Because vesting depends on continued employment, the economic benefit is realized over the vesting period as units convert to shares.